Zhipeng You
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Zhipeng You has a total of 191 co-authors. Here are the top co-authors by number of shared publications:
Huimin Fan
Department of Ophthalmology, The Affiliated Eye Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China
14 shared publicationsKangcheng Liu
Department of Fundus Diseases, The Affiliated Eye Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, 330000, People’s Republic of China
11 shared publicationsFan Gan
Department of Ophthalmology, The Affiliated Eye Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China
6 shared publicationsJian Cao
Department of Ophthalmology, The Affiliated Eye Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China
6 shared publicationsJingying Liu
Jiangxi Province Division of National Clinical Research Center for Ocular Diseases, Jiangxi Clinical Research Center for Ophthalmic Disease, Jiangxi Research Institute of Ophthalmology and Visual Science, Affiliated Eye Hospital of Nanchang University, Nanchang, China
6 shared publicationsQi Wan
Department of Fundus Disease, Affiliated Eye Hospital of Nanchang University, Nanchang, China
6 shared publications
Latest Publications
- Open Access
- 28 September 2026
- Published by Springer Nature in Journal of Translational Medicine
Hypoxia-inducible factor as a master switch in ocular neovascularization: overcoming anti-VEGF resistance and exploring therapeutic prospects
Hypoxia-inducible factor (HIF) is a key driver of ocular neovascular diseases. We systematically discuss its regulatory mechanisms and pathological roles in diabetic retinopathy (DR), retinopathy of prematurity (ROP), and neovascular age-related macular degeneration (nAMD). Upon integration of diverse upstream stimuli—including hypoxia, hyperglycemia, oxidative stress, and inflammatory signals—HIF orchestrates a downstream effector network that drives aberrant neovascularization, vascular leakage, fibrotic remodeling, and neuroretinal degeneration. Current anti-vascular endothelial growth factor (Anti-VEGF) therapies, which block only a single downstream factor, are constrained by inadequate response and resistance. Therefore, pharmacological targeting of the upstream “master switch” HIF represents a promising strategy for achieving broader therapeutic efficacy. In this review, we summarize HIF-targeted strategies at the molecular, clinical, and emerging therapeutic levels,with a focus on the translational progress of lead candidates such as 32-134D and PX-478. Furthermore, the present review highlights the dual role of HIF in physiological vascular development and pathological neovascularization, emphasizing that precise regulation of timing, cell type and microenvironment is critical for therapeutic success. Finally, the limitations of current HIF-targeted therapies and future directions are discussed. Collectively, these insights may support the development of more precise and effective therapies for ocular neovascular diseases.
- 28 September 2026
- Published by Springer Nature in Journal of Translational Medicine
Open AccessHypoxia-inducible factor as a master switch in ocular neovascularization: overcoming anti-VEGF resistance and exploring therapeutic prospects
Hypoxia-inducible factor (HIF) is a key driver of ocular neovascular diseases. We systematically discuss its regulatory mechanisms and pathological roles in diabetic retinopathy (DR), retinopathy of prematurity (ROP), and neovascular age-related macular degeneration (nAMD). Upon integration of diverse upstream stimuli—including hypoxia, hyperglycemia, oxidative stress, and inflammatory signals—HIF orchestrates a downstream effector network that drives aberrant neovascularization, vascular leakage, fibrotic remodeling, and neuroretinal degeneration. Current anti-vascular endothelial growth factor (Anti-VEGF) therapies, which block only a single downstream factor, are constrained by inadequate response and resistance. Therefore, pharmacological targeting of the upstream “master switch” HIF represents a promising strategy for achieving broader therapeutic efficacy. In this review, we summarize HIF-targeted strategies at the molecular, clinical, and emerging therapeutic levels,with a focus on the translational progress of lead candidates such as 32-134D and PX-478. Furthermore, the present review highlights the dual role of HIF in physiological vascular development and pathological neovascularization, emphasizing that precise regulation of timing, cell type and microenvironment is critical for therapeutic success. Finally, the limitations of current HIF-targeted therapies and future directions are discussed. Collectively, these insights may support the development of more precise and effective therapies for ocular neovascular diseases.
- Open Access
- 22 September 2026
- Published by Springer Nature in Journal of Big Data
OphthUS-GPT: a multimodal AI system for ophthalmic B-scan ultrasound report generation and interpretation
- 22 September 2026
- Published by Springer Nature in Journal of Big Data
Open AccessOphthUS-GPT: a multimodal AI system for ophthalmic B-scan ultrasound report generation and interpretation
- 1 September 2026
- Published by Elsevier in Ophthalmology Retina
SSGJ-601 versus Ranibizumab for Macular Edema Secondary to Branch Retinal Vein Occlusion
- 1 September 2026
- Published by Elsevier in Ophthalmology Retina
SSGJ-601 versus Ranibizumab for Macular Edema Secondary to Branch Retinal Vein Occlusion
- Open Access
- 20 August 2026
- Published by Springer Nature in Molecular and Cellular Biochemistry
- Vol. 481 (9) , 4873-4885
Bone marrow fibrocytes and endothelial-to-mesenchymal transition drive pathological ECM remodeling in proliferative diabetic retinopathy
Proliferative diabetic retinopathy (PDR) is characterized by pathological neovascularization and fibrovascular membrane (FVM) formation, yet the cellular origins of fibroblasts within FVMs and vitreous collagen metabolism remain poorly understood. Vitreous humor and FVM specimens were collected from PDR patients and non-diabetic controls undergoing vitrectomy. Immunohistochemistry, enzyme-linked immunosorbent assay (ELISA), and enzymatic activity assays were performed. Double-positive staining for cluster of differentiation (CD)45/collagen type I (COL1) and CD45/S100 calcium-binding protein A4 (S100A4) identified bone marrow-derived fibrocytes, while CD31/COL1 co-expression indicated endothelial-to-mesenchymal transition (EndoMT). Fibronectin was significantly elevated in PDR vitreous (p < 0.01). Matrix metalloproteinase (MMP)-2, MMP-3, and MMP-9 activities were markedly increased in PDR (all P < 0.001), alongside elevated lysyl oxidase (LOX) activity (p < 0.001). Collagen IV detection rates were higher in PDR (63.2% vs. 15%, P < 0.01), and beta cross-linked C-telopeptide of type I collagen (β-CTX) levels were significantly increased (p < 0.001). Notably, total procollagen type I N-terminal propeptide (Total-PINP) was paradoxically elevated in PDR vitreous (p < 0.01), suggesting compensatory collagen synthesis during active neovascularization. These findings demonstrate that FVM fibroblasts originate from multiple sources including bone marrow-derived fibrocytes and EndoMT, and that PDR involves simultaneous MMP-mediated collagen degradation and LOX-mediated cross-linking, providing potential targets for anti-fibrotic therapies.
- 20 August 2026
- Published by Springer Nature in Molecular and Cellular Biochemistry
- Vol. 481 (9) , 4873-4885
Open AccessBone marrow fibrocytes and endothelial-to-mesenchymal transition drive pathological ECM remodeling in proliferative diabetic retinopathy
Proliferative diabetic retinopathy (PDR) is characterized by pathological neovascularization and fibrovascular membrane (FVM) formation, yet the cellular origins of fibroblasts within FVMs and vitreous collagen metabolism remain poorly understood. Vitreous humor and FVM specimens were collected from PDR patients and non-diabetic controls undergoing vitrectomy. Immunohistochemistry, enzyme-linked immunosorbent assay (ELISA), and enzymatic activity assays were performed. Double-positive staining for cluster of differentiation (CD)45/collagen type I (COL1) and CD45/S100 calcium-binding protein A4 (S100A4) identified bone marrow-derived fibrocytes, while CD31/COL1 co-expression indicated endothelial-to-mesenchymal transition (EndoMT). Fibronectin was significantly elevated in PDR vitreous (p < 0.01). Matrix metalloproteinase (MMP)-2, MMP-3, and MMP-9 activities were markedly increased in PDR (all P < 0.001), alongside elevated lysyl oxidase (LOX) activity (p < 0.001). Collagen IV detection rates were higher in PDR (63.2% vs. 15%, P < 0.01), and beta cross-linked C-telopeptide of type I collagen (β-CTX) levels were significantly increased (p < 0.001). Notably, total procollagen type I N-terminal propeptide (Total-PINP) was paradoxically elevated in PDR vitreous (p < 0.01), suggesting compensatory collagen synthesis during active neovascularization. These findings demonstrate that FVM fibroblasts originate from multiple sources including bone marrow-derived fibrocytes and EndoMT, and that PDR involves simultaneous MMP-mediated collagen degradation and LOX-mediated cross-linking, providing potential targets for anti-fibrotic therapies.
- 24 March 2026
- Published by Royal Society of Chemistry (RSC) in Biomaterials Science
- Vol. 14 (8) , 1930-1947
Advances in the application of metal–organic frameworks in ophthalmology
The summary scheme, advantages, applications and challenges of MOFs in ophthalmology.
- 24 March 2026
- Published by Royal Society of Chemistry (RSC) in Biomaterials Science
- Vol. 14 (8) , 1930-1947
Advances in the application of metal–organic frameworks in ophthalmology
The summary scheme, advantages, applications and challenges of MOFs in ophthalmology.
- 11 November 2025
- Published by BMJ in British Journal of Ophthalmology
- Vol. 110 (5) , 576-585
Clinical characteristics and visual recovery in lost-to-follow-up myopic choroidal neovascularization treated with antivascular endothelial growth factor therapy
Background/Aims To identify sociodemographic and clinical factors associated with best-corrected visual acuity (BCVA) restoration at the visit after lost to follow-up (LTFU) in patients with myopic choroidal neovascularization (mCNV) treated with antivascular endothelial growth factor intravitreal injections (IVI). Methods A multicentre, retrospective cohort study was conducted in China of mCNV patients receiving injections who were LTFU >6 months. Data were collected from baseline visit, pre-LTFU, initial post-LTFU visit and 6 months post-LTFU, and the final visit. Logistic regression analyses assessed associations between sociodemographic/clinical factors and BCVA restoration. Results The study included 1155 LTFU patients with mCNV (mean (SD) age: 54 (16) years; 61.6% female), with 66.6% achieving BCVA restoration at the initial post-LTFU visit after LTFU (mean(SD) duration: 315 (154) days. Patients with BCVA restoration were younger (p=0.004), more often from eastern China (p=0.022), and had shorter LTFU duration (p=0.013). Stratification by pre-LTFU BCVA showed that patients with BCVA ≥20/40 had lower restoration odds (OR 0.65, 95% CI 0.44 to 0.96; p=0.032) compared with those with BCVA 280 µm had higher BCVA restoration odds (OR 1.98, 95% CI 1.02 to 3.92; p=0.046). Conclusions Better pre-LTFU BCVA (≥20/40) increased post-LTFU deterioration risk (associated with progressive CST thickening), while elevated post-LTFU CST (>280 µm) predicted higher BCVA restoration odds in patients with sustained follow-up, supporting CST-guided monitoring and early intervention for high-risk groups.
- 11 November 2025
- Published by BMJ in British Journal of Ophthalmology
- Vol. 110 (5) , 576-585
Clinical characteristics and visual recovery in lost-to-follow-up myopic choroidal neovascularization treated with antivascular endothelial growth factor therapy
Background/Aims To identify sociodemographic and clinical factors associated with best-corrected visual acuity (BCVA) restoration at the visit after lost to follow-up (LTFU) in patients with myopic choroidal neovascularization (mCNV) treated with antivascular endothelial growth factor intravitreal injections (IVI). Methods A multicentre, retrospective cohort study was conducted in China of mCNV patients receiving injections who were LTFU >6 months. Data were collected from baseline visit, pre-LTFU, initial post-LTFU visit and 6 months post-LTFU, and the final visit. Logistic regression analyses assessed associations between sociodemographic/clinical factors and BCVA restoration. Results The study included 1155 LTFU patients with mCNV (mean (SD) age: 54 (16) years; 61.6% female), with 66.6% achieving BCVA restoration at the initial post-LTFU visit after LTFU (mean(SD) duration: 315 (154) days. Patients with BCVA restoration were younger (p=0.004), more often from eastern China (p=0.022), and had shorter LTFU duration (p=0.013). Stratification by pre-LTFU BCVA showed that patients with BCVA ≥20/40 had lower restoration odds (OR 0.65, 95% CI 0.44 to 0.96; p=0.032) compared with those with BCVA 280 µm had higher BCVA restoration odds (OR 1.98, 95% CI 1.02 to 3.92; p=0.046). Conclusions Better pre-LTFU BCVA (≥20/40) increased post-LTFU deterioration risk (associated with progressive CST thickening), while elevated post-LTFU CST (>280 µm) predicted higher BCVA restoration odds in patients with sustained follow-up, supporting CST-guided monitoring and early intervention for high-risk groups.
- Open Access
- 7 November 2025
- Published by Springer Nature in BMC Ophthalmology
- Vol. 25 (1) , 1-10
Phacoemulsification combined with goniosynechialysis for acute angle-closure glaucoma: impact of preoperative IOP status
Treatment of acute angle-closure glaucoma with phacoemulsification combined with goniosynechialysis significantly improves patients’ visual acuity and reduce intraocular pressure; the preoperative condition has minimal influence on the treatment outcome. The study aimed to treat acute angle-closure glaucoma and explore the structural differences of the anterior segment as well as the influence of persistent high intraocular pressure on surgical outcomes. This retrospective case-control study included 120 patients (122 eyes) with acute angle-closure glaucoma, divided into two groups based on intraocular pressure two hours post-drug treatment: a normotensive group (21 mmHg or below; 54 subjects/55 eyes) and a hypertensive group (> 21 mmHg; 66 patients/67 eyes). Anterior segment structures, corneal endothelial cell density, and other parameters were systematically analyzed. All patients underwent phacoemulsification combined with goniosynechialysis. Statistical analysis employed independent-samples t-tests, Mann-Whitney U tests, and Wilcoxon signed-rank tests, as appropriate. There was no significant difference in the anterior segment structure between the two groups (P > 0.05) except for anterior chamber depth (t = -2.541, P = 0.012). Corneal endothelial cell density was significantly higher in the normotensive group than in the hypertensive group (Z = -0.399, P = 0.026).Postoperative visual acuity improved in both groups (Z = -8.663, P < 0.01), but no significant intergroup difference was observed (Z = -1.201, P = 0.23).Intraocular pressure decreased significantly in both groups (t = 25.901, P < 0.01). with a more pronounced reduction in the hypertensive group (Z = -3.387, P = 0.01). In medically treated acute angle-closure glaucoma, anterior chamber depth differed significantly between the normotensive and hypertensive groups ( P = 0.012), whereas no significant differences were observed in other anterior segment parameters (P > 0.05). Following phacoemulsification combined with goniosynechialysis, both visual acuity and intraocular improved. Preoperative persistent high intraocular pressure has no significant effect on surgical outcomes.
- 7 November 2025
- Published by Springer Nature in BMC Ophthalmology
- Vol. 25 (1) , 1-10
Open AccessPhacoemulsification combined with goniosynechialysis for acute angle-closure glaucoma: impact of preoperative IOP status
Treatment of acute angle-closure glaucoma with phacoemulsification combined with goniosynechialysis significantly improves patients’ visual acuity and reduce intraocular pressure; the preoperative condition has minimal influence on the treatment outcome. The study aimed to treat acute angle-closure glaucoma and explore the structural differences of the anterior segment as well as the influence of persistent high intraocular pressure on surgical outcomes. This retrospective case-control study included 120 patients (122 eyes) with acute angle-closure glaucoma, divided into two groups based on intraocular pressure two hours post-drug treatment: a normotensive group (21 mmHg or below; 54 subjects/55 eyes) and a hypertensive group (> 21 mmHg; 66 patients/67 eyes). Anterior segment structures, corneal endothelial cell density, and other parameters were systematically analyzed. All patients underwent phacoemulsification combined with goniosynechialysis. Statistical analysis employed independent-samples t-tests, Mann-Whitney U tests, and Wilcoxon signed-rank tests, as appropriate. There was no significant difference in the anterior segment structure between the two groups (P > 0.05) except for anterior chamber depth (t = -2.541, P = 0.012). Corneal endothelial cell density was significantly higher in the normotensive group than in the hypertensive group (Z = -0.399, P = 0.026).Postoperative visual acuity improved in both groups (Z = -8.663, P < 0.01), but no significant intergroup difference was observed (Z = -1.201, P = 0.23).Intraocular pressure decreased significantly in both groups (t = 25.901, P < 0.01). with a more pronounced reduction in the hypertensive group (Z = -3.387, P = 0.01). In medically treated acute angle-closure glaucoma, anterior chamber depth differed significantly between the normotensive and hypertensive groups ( P = 0.012), whereas no significant differences were observed in other anterior segment parameters (P > 0.05). Following phacoemulsification combined with goniosynechialysis, both visual acuity and intraocular improved. Preoperative persistent high intraocular pressure has no significant effect on surgical outcomes.
- 30 August 2025
- Published by Springer Nature in International Ophthalmology
- Vol. 45 (1) , 1-8
Pars plana vitrectomy followed by subretinal or intravitreal injection with Conbercept and tissue plasminogen activator for clearance of submacular hemorrhage secondary to idiopathic polypoidal choroidal vasculopathy
Purpose The optimal treatment approach for submacular hemorrhage (SMH) secondary to idiopathic polypoid choroidal vasculopathy (IPCV) remains uncertain. This study aimed to explore the prognosis and complications of pars plana vitrectomy (PPV) followed by subretinal or intravitreal injection with Conbercept (0.05 ml, 10 mg/ml) and tissue plasminogen activator (t-PA) (0.05 ml ~ 0.1 ml, 0.25 mg/ml) for submacular hemorrhage (SMH) secondary to IPCV. Methods This retrospective study included patients with SMH secondary to IPCV who received PPV followed by subretinal or intravitreal injection with Conbercept and t-PA at the Affiliated Eye Hospital of Nanchang University between March and November 2023. The rate of SMH clearance, best corrected visual acuity (BCVA), and central macular thickness (CMT), and postoperative complications at 1 week, 1 month, 3 months and 6 months post-treatment were collected. Results A total of 41 patients were included, with 22 (8 males, 14 left eyes) of who received subretinal injection.Patients who received subretinal injection showed significantly less times of injections (P = 0.008), compared with those received intravitreal injection. Repeated measurement analysis showed that, compared with intravitreal injection, patients who received subretinal injection exhibited significant higher SMH clearance ratio (P < 0.001), while comparable BCVA (P = 0.942) and CMT (0.906). In addition, the occurrence of postoperative complications, including vitreous hemorrhage (P = 0.999) and macular hemorrhage (P = 0.463), between those received subretinal and intravitreal injection were similar. Conclusion Compared with intravitreal injection, PPV followed by subretinal injection with Conbercept and t-PA might be a more optimal protocol with higher SMH clearance ratio for SMH Secondary to IPCV.
- 30 August 2025
- Published by Springer Nature in International Ophthalmology
- Vol. 45 (1) , 1-8
Pars plana vitrectomy followed by subretinal or intravitreal injection with Conbercept and tissue plasminogen activator for clearance of submacular hemorrhage secondary to idiopathic polypoidal choroidal vasculopathy
Purpose The optimal treatment approach for submacular hemorrhage (SMH) secondary to idiopathic polypoid choroidal vasculopathy (IPCV) remains uncertain. This study aimed to explore the prognosis and complications of pars plana vitrectomy (PPV) followed by subretinal or intravitreal injection with Conbercept (0.05 ml, 10 mg/ml) and tissue plasminogen activator (t-PA) (0.05 ml ~ 0.1 ml, 0.25 mg/ml) for submacular hemorrhage (SMH) secondary to IPCV. Methods This retrospective study included patients with SMH secondary to IPCV who received PPV followed by subretinal or intravitreal injection with Conbercept and t-PA at the Affiliated Eye Hospital of Nanchang University between March and November 2023. The rate of SMH clearance, best corrected visual acuity (BCVA), and central macular thickness (CMT), and postoperative complications at 1 week, 1 month, 3 months and 6 months post-treatment were collected. Results A total of 41 patients were included, with 22 (8 males, 14 left eyes) of who received subretinal injection.Patients who received subretinal injection showed significantly less times of injections (P = 0.008), compared with those received intravitreal injection. Repeated measurement analysis showed that, compared with intravitreal injection, patients who received subretinal injection exhibited significant higher SMH clearance ratio (P < 0.001), while comparable BCVA (P = 0.942) and CMT (0.906). In addition, the occurrence of postoperative complications, including vitreous hemorrhage (P = 0.999) and macular hemorrhage (P = 0.463), between those received subretinal and intravitreal injection were similar. Conclusion Compared with intravitreal injection, PPV followed by subretinal injection with Conbercept and t-PA might be a more optimal protocol with higher SMH clearance ratio for SMH Secondary to IPCV.
- 7 May 2025
- Published by Wiley in Cell Biology International
- Vol. 49 (7) , 852-864
Isoquercetin Alleviates Diabetic Retinopathy Via Inhibiting p53‐Mediated Ferroptosis
Diabetic retinopathy (DR) is a retinal vasculopathy stemming from diabetes mellitus, characterized by microvascular changes in the retina that can lead to visual impairment or even blindness. Ferroptosis, a form of regulated cell death driven by iron accumulation and lipid peroxidation, has been implicated in the progression of DR. Isoquercetin (IQC), a flavonoid compound, has been shown to inhibit cellular ferroptosis and apoptosis, yet its specific role and underlying mechanisms in DR remain to be elucidated. The present study aimed to investigate the effects of IQC on DR and to delineate its protective mechanisms, particularly focusing on whether these effects are mediated through p53. We employed streptozotocin‐induced diabetic C57BL/J mouse models and high glucose (HG)‐induced human retinal capillary endothelial cells (HRCECs) models for both in vivo and in vitro experiments. Pathological damage was assessed using hematoxylin and eosin staining, while cell apoptosis rates was detected by TUNEL staining and FITC/PI flow cytometry. Mitochondrial damage was evaluated using transmission electron microscopy. Additionally, we measured levels of reactive oxygen species (ROS) and glutathione (GSH) to assess lipid peroxidation and quantified ferrous ions (Fe2+). Protein expression was detected by immunofluorescence and western blot analysis, and mRNA levels were determined by real‐time quantitative PCR. Our findings revealed that IQC mitigated retinal damage in diabetic mice, and in vitro studies further demonstrated that this effect was mediated by the inhibition of p53. In HG‐induced HRCECs, we observed decreased cell viability, lipid peroxidation, and ferroptosis. IQC alleviated HG‐induced ferroptosis in HRCECs by modulating the p53 pathway, which exhibited varying responses following p53 inhibition or activation. In summary, IQC downregulated the p53 signaling pathway, thereby reducing ferroptosis and apoptosis, and effectively ameliorated the damage associated with DR. These discoveries offer novel insights into the protective mechanisms of IQC in DR.
- 7 May 2025
- Published by Wiley in Cell Biology International
- Vol. 49 (7) , 852-864
Isoquercetin Alleviates Diabetic Retinopathy Via Inhibiting p53‐Mediated Ferroptosis
Diabetic retinopathy (DR) is a retinal vasculopathy stemming from diabetes mellitus, characterized by microvascular changes in the retina that can lead to visual impairment or even blindness. Ferroptosis, a form of regulated cell death driven by iron accumulation and lipid peroxidation, has been implicated in the progression of DR. Isoquercetin (IQC), a flavonoid compound, has been shown to inhibit cellular ferroptosis and apoptosis, yet its specific role and underlying mechanisms in DR remain to be elucidated. The present study aimed to investigate the effects of IQC on DR and to delineate its protective mechanisms, particularly focusing on whether these effects are mediated through p53. We employed streptozotocin‐induced diabetic C57BL/J mouse models and high glucose (HG)‐induced human retinal capillary endothelial cells (HRCECs) models for both in vivo and in vitro experiments. Pathological damage was assessed using hematoxylin and eosin staining, while cell apoptosis rates was detected by TUNEL staining and FITC/PI flow cytometry. Mitochondrial damage was evaluated using transmission electron microscopy. Additionally, we measured levels of reactive oxygen species (ROS) and glutathione (GSH) to assess lipid peroxidation and quantified ferrous ions (Fe2+). Protein expression was detected by immunofluorescence and western blot analysis, and mRNA levels were determined by real‐time quantitative PCR. Our findings revealed that IQC mitigated retinal damage in diabetic mice, and in vitro studies further demonstrated that this effect was mediated by the inhibition of p53. In HG‐induced HRCECs, we observed decreased cell viability, lipid peroxidation, and ferroptosis. IQC alleviated HG‐induced ferroptosis in HRCECs by modulating the p53 pathway, which exhibited varying responses following p53 inhibition or activation. In summary, IQC downregulated the p53 signaling pathway, thereby reducing ferroptosis and apoptosis, and effectively ameliorated the damage associated with DR. These discoveries offer novel insights into the protective mechanisms of IQC in DR.
- Open Access
- 28 April 2025
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 29 (9) , e70521
Target Screening and Single Cell Analysis of Diabetic Retinopathy and Hepatocarcinoma
The association between liver cancer and diabetes has been a longstanding focus in medical research. Current evidence suggests that diabetes is an independent risk factor for the development of liver cancer. Diabetic retinopathy (DR), a prevalent neurovascular complication of diabetes, has yet to be fully characterised concerning liver cancer. Therefore, this study seeks to identify shared genes and pathways between liver cancer and DR to uncover potential therapeutic targets. Immune infiltration and cell communication in liver cancer were analysed using the GEO single‐cell dataset GSM7494113. Single‐cell RNA sequencing data from rat retinas were obtained from the GEO datasets GSE209872 and GSE160306. Ferritin phagocytosis‐related genes were retrieved from the GeneCards database. The SeuratR package was employed for single‐cell clustering analysis, while the CellChat package assessed differences in intercellular communication. Genes shared between DR and liver cancer were identified, and the DGIDB database was consulted to predict potential drug‐gene interactions targeting membrane proteins involved in ferritin phagocytosis. Key ferritin phagocytosis (FRHG) genes were further validated using quantitative real‐time polymerase chain reaction (qRT‐PCR). After annotating the single‐cell data through dimensionality reduction and clustering, the expression of genes associated with membrane protein‐related ferritinophagy was notably elevated in both HCC and DR samples. Based on the expression of ferritinophagy‐related genes, the ferritin deposition score in Müller cells from the DR group was significantly higher than that in the control group. Cell communication analysis revealed that central hub genes associated with ferritinophagy, such as PSAP and MK, along with other signalling pathways, were significantly upregulated in the high Müller group compared to the low Müller group. In contrast, VEGF expression was enhanced in the low Müller group. Importantly, the machine learning model constructed using these key hub genes demonstrated high diagnostic efficacy for both HCC and DR. Finally, by simulating a hyperosmotic diabetic microenvironment, we confirmed in vitro that high glucose conditions significantly stimulate the expression of the shared key hub genes in both HCC and DR. The present study identified the connection between ferritinophagy‐related subgroups of cells and key hub genes in both HCC and DR, providing new insights into DR‐associated biomarkers and the shared pathological regulatory pathways with HCC. These findings further suggest potential therapeutic targets for both diseases.
- 28 April 2025
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 29 (9) , e70521
Open AccessTarget Screening and Single Cell Analysis of Diabetic Retinopathy and Hepatocarcinoma
The association between liver cancer and diabetes has been a longstanding focus in medical research. Current evidence suggests that diabetes is an independent risk factor for the development of liver cancer. Diabetic retinopathy (DR), a prevalent neurovascular complication of diabetes, has yet to be fully characterised concerning liver cancer. Therefore, this study seeks to identify shared genes and pathways between liver cancer and DR to uncover potential therapeutic targets. Immune infiltration and cell communication in liver cancer were analysed using the GEO single‐cell dataset GSM7494113. Single‐cell RNA sequencing data from rat retinas were obtained from the GEO datasets GSE209872 and GSE160306. Ferritin phagocytosis‐related genes were retrieved from the GeneCards database. The SeuratR package was employed for single‐cell clustering analysis, while the CellChat package assessed differences in intercellular communication. Genes shared between DR and liver cancer were identified, and the DGIDB database was consulted to predict potential drug‐gene interactions targeting membrane proteins involved in ferritin phagocytosis. Key ferritin phagocytosis (FRHG) genes were further validated using quantitative real‐time polymerase chain reaction (qRT‐PCR). After annotating the single‐cell data through dimensionality reduction and clustering, the expression of genes associated with membrane protein‐related ferritinophagy was notably elevated in both HCC and DR samples. Based on the expression of ferritinophagy‐related genes, the ferritin deposition score in Müller cells from the DR group was significantly higher than that in the control group. Cell communication analysis revealed that central hub genes associated with ferritinophagy, such as PSAP and MK, along with other signalling pathways, were significantly upregulated in the high Müller group compared to the low Müller group. In contrast, VEGF expression was enhanced in the low Müller group. Importantly, the machine learning model constructed using these key hub genes demonstrated high diagnostic efficacy for both HCC and DR. Finally, by simulating a hyperosmotic diabetic microenvironment, we confirmed in vitro that high glucose conditions significantly stimulate the expression of the shared key hub genes in both HCC and DR. The present study identified the connection between ferritinophagy‐related subgroups of cells and key hub genes in both HCC and DR, providing new insights into DR‐associated biomarkers and the shared pathological regulatory pathways with HCC. These findings further suggest potential therapeutic targets for both diseases.